Etirinotecan pegol

Etirinotecan pegol

Etirinotecan pegol (pronunciation: eh-tee-ri-no-tee-kan pee-gol) is a polyethylene glycol (PEG) conjugate of irinotecan, a topoisomerase I inhibitor. It is a novel anticancer drug designed to provide prolonged systemic exposure to active drug metabolites.

Etymology

The name "Etirinotecan pegol" is derived from its chemical structure. "Eti" refers to the ethyl group in its structure, "irinotecan" is the parent drug, and "pegol" indicates that it is a PEGylated compound.

Mechanism of Action

Etirinotecan pegol is a prodrug that is converted in the body to SN-38, the active metabolite of irinotecan. SN-38 binds to the nuclear enzyme topoisomerase I, which relaxes supercoiled DNA for transcription. By inhibiting this enzyme, DNA replication and transcription are disrupted, leading to cell death.

Clinical Use

Etirinotecan pegol is used in the treatment of patients with advanced breast cancer who have previously received an anthracycline and a taxane. It has also been studied in other types of cancer, including colorectal cancer and lung cancer.

Side Effects

Common side effects of etirinotecan pegol include neutropenia, diarrhea, nausea, vomiting, and fatigue. Severe side effects can include neutropenic sepsis and severe diarrhea.

Related Terms

• Irinotecan
• Topoisomerase I inhibitor
• Prodrug
• Polyethylene glycol
• Anticancer drug
• Breast cancer
• Colorectal cancer
• Lung cancer
• Neutropenia
• Diarrhea
• Nausea
• Vomiting
• Fatigue
• Neutropenic sepsis

External links

• Medical encyclopedia article on Etirinotecan pegol
• Wikipedia's article - Etirinotecan pegol

This WikiMD article is a stub. You can help make it a full article.

---

Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski